
- Oncology NEWS International Vol 15 No 8
- Volume 15
- Issue 8
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
More than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years
ATLANTAMore than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years, according to a retrospective analysis. Sven Henrik Stbinger, MD, of the University Hospital Kiel, Germany, presented the results at the American Urological Association 101st Annual Meeting (abstract 1137).
Surveys were offered to 805 men who were treated with external percutaneous radiation (70 Gy) and dose-escalating high-dose-rate brachytherapy between 1986 and 2002. Men either filled out questionnaires or were interviewed by phone. In survey results from 510 men, the most common short-term side effects included various voiding dysfunctions and diarrhea, including leakage (17%), alguria (14%), diarrhea (13%), and residual urine (12%). Late-onset side effects included proctitis (10%), incontinence (6%), urethral stricture (5%), cystitis (3%), stool incontinence (3%), fistula (1%), and urinary retention (1%).
Of the 299 men who provided information on potency, 33% reported erectile dysfunction that had developed since their treatment. "It is very difficult in a retrospective style to get information from patients before the treatment," Dr. Stbinger said at a press briefing. He noted that these retrospective results do give an idea of what clinicians, researchers, and patients might expect.
Articles in this issue
about 19 years ago
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcomeabout 19 years ago
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemoabout 19 years ago
Triple Targeted Therapy Is Tested in Pts With Solid Tumorsabout 19 years ago
FDA Approves Three-Drug Combination Tablet for HIV-1about 19 years ago
No Significant QOL Differences for Raloxifene and Tamoxifenabout 19 years ago
Amrubicin Appears Promising in Small-Cell Lung Cancerabout 19 years ago
R-MP Active in Older Pts With Newly Diagnosed Myelomaabout 19 years ago
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trialsabout 19 years ago
Takeda Signs Agreement With Galaxy Biotech for HuL2G7about 19 years ago
Experimental Regimens Fail to Boost Pancreatic SurvivalNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.